Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Non-surgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness

Slide: 39 of 50

Adverse Effects of Pharmacological Interventions for Urgency UI: Placebo Comparisons (2 of 2)

Other adverse effects of pharmacological interventions include the two most commonly reported, dry mouth and constipation, along with others that include but are not limited to dry eye, blurred vision, and dyspepsia.

For darifenacin, 5 studies of 2,382 participants reported dry mouth at a rate of 158 events attributable to darifenacin per 1,000 treated patients, with a statistically valid range from 65 to 269 reports. Five studies of 2,239 participants reported constipation at a rate of 80 reports attributable to darifenacin per 1,000 treated patients, with a statistically valid range of 24 to 148 reports per 1,000 treated patients. Another adverse effect often reported with darifenacin is dyspepsia. Four studies of 1,772 participants recorded 31 reports of dyspepsia per 1,000 participants treated with darifenacin, with a statistically valid range from 7 to 62 reports. The strength of evidence in support of the findings for darifenacin is high.

For fesoterodine, 5 studies of 6,674 participants reported dry mouth at a rate of 199 events attributable to fesoterodine per 1,000 treated patients, with a statistically valid range from 161 to 239 reports. Seven studies of 7,695 participants reported constipation at a rate of 41 reports attributable to fesoterodine per 1,000 treated patients, with a statistically valid range of 1 to 97 reports. Another adverse effect often reported with fesoterodine is dry eye. Four studies of 1,772 participants recorded 31 reports of dry eye per 1,000 participants treated with fesoterodine, with a statistically valid range from 7 to 62 reports. The strength of evidence in support of the findings for fesoterodine is high.

For oxybutynin, 9 studies of 2,238 participants reported dry mouth at a rate of 347 events attributable to oxybutynin per 1,000 treated patients, with a statistically valid range from 158 to 536 reports. The strength of evidence for this finding is high. Seven studies of 1,743 participants reported constipation at a rate of 73 reports attributable to oxybutynin per 1,000 treated patients, with a statistically valid range of 49 to 99 reports. The strength of evidence for this finding is moderate. Another adverse effect often reported with oxybutynin is dyspepsia. Three studies of 613 participants recorded 85 reports of dyspepsia per 1,000 participants treated with oxybutynin, with a statistically valid range from 10 to 26 reports. The strength of evidence in support of this finding is moderate.

For solifenacin, 7 studies of 11,089 participants reported dry mouth at a rate of 175 events attributable to solifenacin per 1,000 treated patients, with a statistically valid range from 122 to 232 reports. The strength of evidence for this finding is high. Eight studies of 11,765 participants reported constipation at a rate of 73 reports attributable to solifenacin per 1,000 treated patients, with a statistically valid range of 49 to 99 reports. The strength of evidence for this finding is high. Another adverse effect often reported with solifenacin is blurred vision. Nine studies of 12,922 participants recorded 17 reports of blurred vision per 1,000 participants treated with oxybutynin, with a statistically valid range from 10 to 26 reports. The strength of evidence in support of this finding is high.

For tolterodine, 14 studies of 7,637 participants reported dry mouth at a rate of 139 events attributable to solifenacin per 1,000 treated patients, with a statistically valid range from 122 to 232 reports. The strength of evidence for this finding is high. Eight studies of 11,765 participants reported constipation at a rate of 139 reports attributable to solifenacin per 1,000 treated patients, with a statistically valid range of 104 to 175 reports. The strength of evidence for this finding is high. Another adverse effect often reported with tolterodine is dyspepsia. Six studies of 3,525 participants recorded 22 reports of blurred vision per 1,000 participants treated with oxybutynin, with a statistically valid range from 1 to 53 reports. The strength of evidence in support of this finding is high.

For trospium, 6 studies of 3,490 participants reported dry mouth at a rate of 106 events attributable to tolterodine per 1,000 treated patients, with a statistically valid range from 75 to 140 reports. The strength of evidence for this finding is low. Five studies of 3,335 participants reported constipation at a rate of 70 reports attributable to trospium per 1,000 treated patients, with a statistically valid range of 47 to 95 reports. The strength of evidence for this finding is high. Another adverse effect often reported with trospium is dry eye. Two studies of 1,590 participants recorded 14 reports of blurred vision per 1,000 participants treated with oxybutynin, with a statistically valid range from 4 to 29 reports. The strength of evidence in support of this finding is low.